Masatoshi Maeki

Prof. Masatoshi Maeki

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
MMMasatoshi Maeki
Masatoshi Maeki
SUShuya Uno
Shuya Uno
ANAyuka Niwa
Ayuka Niwa
YOYuto Okada
Yuto Okada
MTManabu Tokeshi
Manabu Tokeshi

1 March 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
MMMasatoshi Maeki
Masatoshi Maeki
NKNiko Kimura
Niko Kimura
YSYusuke Sato
Yusuke Sato
HHHideyoshi Harashima
Hideyoshi Harashima
MTManabu Tokeshi
Manabu Tokeshi

9 May 2018 in ACS Omega
Verified
Journal Article
Open access
NKNiko Kimura
Niko Kimura
MMMasatoshi Maeki
Masatoshi Maeki
YSYusuke Sato
Yusuke Sato
YNYusuke Note
Yusuke Note
AIAkihiko Ishida
Akihiko Ishida
MTManabu Tokeshi
Manabu Tokeshi
The precise size control of the lipid nanoparticle (LNP)-based nanodrug delivery system (DDS) carriers, such as 10 nm size tuning of LNPs, is one major challenge for the development of next-generation nanomedicines. Size-controlled LNPs would realize size-selective tumor targeting and deliver DNA and RNA to target tumor tissues effectively by passing through the stromal cells. Herein, we developed a baffle mixer device named the invasive lipid nanoparticle production device, or iLiNP device for short, which has a simple two-dimensional microchannel and mixer structure, and we achieved the first reported LNP size tuning at 10 nm intervals in the size range from 20 to 100 nm. In comparison with the conventional LNP preparation methods and reported micromixer devices, our iLiNP device showed better LNP size controllability, robustness of device design, and LNP productivity. Furthermore, we prepared 80 nm sized LNPs with encapsulated small interfering RNA (siRNA) using the iLiNP device; these LNPs effectively performed as nano-DDS carriers in an in vivo experiment. We expect iLiNP devices will become novel apparatuses for LNP production in nano-DDS applications.

30 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYubo Wang
Yubo Wang
JQJose Enrico Quijano Quinsaat
Jose Enrico Quijano Quinsaat
TOTomoko Ono
Tomoko Ono
MMMasatoshi Maeki
Masatoshi Maeki
MTManabu Tokeshi
Manabu Tokeshi
TYTakuya Yamamoto
Takuya Yamamoto
Nano-sized metal particles are attracting much interest in industrial and biomedical applications due to the recent progress and development of nanotechnology, and the surface-modifications by appropriate polymers are key techniques to stably express their characteristics. Herein, we applied cyclic poly(ethylene glycol) (c-PEG), having no chemical inhomogeneity, to provide a polymer topology-dependent stabilization for the surface-modification of gold nanoparticles (AuNPs) through physisorption. By simply mixing c-PEG, but not linear counterparts, enables AuNPs to maintain dispersibility through freezing, lyophilization, or heating. Surprisingly, c-PEG endowed AuNPs with even better dispersion stability than thiolated PEG (HS–PEG–OMe). The stronger affinity of c-PEG was confirmed by DLS, ζ-potential, and FT-IR. Furthermore, the c-PEG system exhibited prolonged blood circulation and enhanced tumor accumulation in mice. Our data suggests that c-PEG induces physisorption on AuNPs, supplying sufficient stability toward bio-medical applications, and would be an alternative approach to the gold–sulfur chemisorption.

28 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMasatoshi Maeki
Masatoshi Maeki
YFYuka Fujishima
Yuka Fujishima
YSYusuke Sato
Yusuke Sato
TYTakao Yasui
Takao Yasui
NKNoritada Kaji
Noritada Kaji
MTManabu Tokeshi
Manabu Tokeshi
Lipid nanoparticles (LNPs) or liposomes are the most widely used drug carriers for nanomedicines. The size of LNPs is one of the essential factors affecting drug delivery efficiency and therapeutic efficiency. Here, we demonstrated the effect of lipid concentration and mixing performance on the LNP size using microfluidic devices with the aim of understanding the LNP formation mechanism and controlling the LNP size precisely. We fabricated microfluidic devices with different depths, 11 μm and 31 μm, of their chaotic micromixer structures. According to the LNP formation behavior results, by using a low concentration of the lipid solution and the microfluidic device equipped with the 31 μm chaotic mixer structures, we were able to produce the smallest-sized LNPs yet with a narrow particle size distribution. We also evaluated the mixing rate of the microfluidic devices using a laser scanning confocal microscopy and we estimated the critical ethanol concentration for controlling the LNP size. The critical ethanol concentration range was estimated to be 60–80% ethanol. Ten nanometer-sized tuning of LNPs was achieved for the optimum residence time at the critical concentration using the microfluidic devices with chaotic mixer structures. The residence times at the critical concentration necessary to control the LNP size were 10, 15–25, and 50 ms time-scales for 30, 40, and 50 nm-sized LNPs, respectively. Finally, we proposed the LNP formation mechanism based on the determined LNP formation behavior and the critical ethanol concentration. The precise size-controlled LNPs produced by the microfluidic devices are expected to become carriers for next generation nanomedicines and they will lead to new and effective approaches for cancer treatment.

28 January 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TNTakashi Nakamura
Takashi Nakamura
MKMinori Kawai
Minori Kawai
YSYusuke Sato
Yusuke Sato
MMMasatoshi Maeki
Masatoshi Maeki
MTManabu Tokeshi
Manabu Tokeshi
HHHideyoshi Harashima
Hideyoshi Harashima